A respected medical journal recently cited Dawn AC anticoagulation management software as a safe and effective way to provide dosage for patients. The scientific article, published in Thrombosis and Haemostasis, also revealed other significant findings related to the widely-used Dawn AC warfarin software.
Cumbria, England -- Dawn AC's computer-dosage program has proven to be "...as safe clinically for patients as manual dosage by experienced medical staff," according to an article in a recent issue of Thrombosis and Haemostasis (Thromb Haemost 2009; 101:487-494). Led by Professor Leon Poller of the University of Manchester, UK, the scholarly report was authored by a group of eminent thrombosis physicians mainly in Europe and around the world.
The report referenced a large international clinical trial of the Dawn AC computer-assisted oral anticoagulant dosage program. The five-year study involved 2631 patients who were randomized to either manual or computer-assisted dosage in 13 centers around the world.
The Dawn AC program provided dosage for a variety of drugs, including warfarin, nicoumalone (Acenocoumarol) and phenprocoumon. The results were impressive:
· Clinical events of bleeding and thrombosis were almost identical.
· Therapeutic INR control improved from 63.4 percent with manual dosage to 66.8 percent with Dawn AC. (These results are particularly significant given that 2,099 or 80 percent of the patients were new to anticoagulation.) This difference between the two legs of the trial was statistically highly significant in terms of INR control.
"The results should reassure hospitals and community clinics that the Dawn AC program is safe and facilitate greater and longer provision of warfarin in treatment where required," the article stated.
Dawn AC's favorable assessment is significant for a number of reasons. Computer-assisted oral anticoagulant dosage is being increasingly used worldwide to satisfy the rising demand for oral anticoagulation. The Dawn AC warfarin software is one of the most widely-used computer-dosage programs. Proof of the value of such computer programs previously has been validated by laboratory end-point "time in range" studies rather than clinical safety. The recent research clearly confirms the safety of Dawn AC and contains major implications.
"The results of this study, which is one of the largest every undertaken in oral anticoagulation, should be, therefore, reassuring to hospitals and community clinics wishing to move to computer-assisted dosage with the Dawn AC program to reduce heavy demands on medical staff time and resources," the report concluded.
The journal article also noted that software differs from vendor to vendor, and it cannot be assumed that Dawn AC's results can be transferred to other products. Each product should be independently evaluated.
Dawn AC, which is manufactured by UK-based 4S Information Systems Ltd., has become the "gold" standard of anticoagulation monitoring and management. To date, an estimated 500,000 patients are monitored approximately six million times per year using Dawn AC software. The popular warfarin software offers complete anticoagulation life cycle and support for community-based therapy. It can be used to establish a shared, integrated-care solution between primary and secondary care.
About 4S Information Systems Ltd.
Established in 1984, 4S Information Systems is a leading manufacturer of clinical software. In addition to Dawn AC software, the company also manufactures products for tracking rheumatology, anemia and hematology patients. 4S Information Systems is headquartered in North West England near Manchester and trades under the name 4S Dawn Clinical Software.
To learn more about Dawn AC anticoagulation software, please visit www.4s-dawn.com. Or contact Managing Director Syd Stewart directly at 44 15395 63091.
Read the full story at http://www.prweb.com/releases/2009/03/prweb2256724.htm.
Copyright©2009 Vocus, Inc.
All rights reserved